BTK and B-cell chronic lymphocytic leukemia: (27) evaluated serially collected PB samples from CLL patients treated with ibrutinib (BTK/ITK inhibitor; n = 19) or acalabrutinib (selective BTK inhibitor; n = 13) in second or further line of treatment.